Zie ook dit artikel:
en dit artikel:
En zie ook:
8 december 2021: Bron: PLoS One. 2021; 16(3): e0247293. Published online 2021 Mar 10. The 2021 Society for Neuro-Oncology’s 26th Annual Scientific Meeting and Education Day, from November 18 – 21
Een kleine fase I/II studie bij totaal 14 patiënten met een recidief van een hersentumor van het type glioblastoma multiforme heeft veelbelovende resultaten laten zien voor een vorm van immuuntherapie met natural killercellen en opgekweekte autologe T-cellen verkregen uit bloed of uit de lymfeklieren van de patiënten zelf. (In het Engels heet dit: Autologous adoptive immune-cell therapy). (Zie ook deze studie uit 2004: Autologous Natural Killer Cell Therapy for Human Recurrent Malignant Glioma)
Van de oorspronkelijk 16 geselecteerde patiënten bleven er 14 over voor de analyse van een open label fase I/II veiligheidstudie. Van die 14 patiënten overleden er 9 door progressie van hun ziekte tijdens de onderzoeksperiode, maar 5 patiënten overleefden langer dan 2 jaar. De mediane overall overleving was 22 maanden en progressievrije ziekte was mediaan 10 maanden. Belangrijk ook was dat ten gevolge van de autologe adoptieve immuuntherapie er slechts graad 1 en 2 bijwerkingen werden gezien die heel gemakkelijk waren te controleren. Alle patiënten hadden eerder standaard behandelingen gehad van chemo (temozolomide - temodal) en bestraling maar hadden ook allemaal een recidief gekregen. Bedenk dat de mediane overall overleving voor deze groep van patiënten slechts 4 maanden bedraagt historisch gezien.
De gemiddelde leeftijd bij de diagnose in de GBM-groep met een aantoonbaar recidief en die met adoptie-immuuncellen werden behandeld, was 53 jaar (standaarddeviatie: 9,5, leeftijdsbereik: 27-69).
Van de 14 patiënten waren respectievelijk 42,9% en 57,1% man en vrouw.
De isocitraatdehydrogenase IDH1-mutatie, R132H, werd gedetecteerd bij één patiënt.
Adjuvante chemotherapie en radiotherapie werden gebruikt als palliatieve behandeling; gedetailleerde baseline-informatie en klinische kenmerken van de 14 patiënten worden gegeven in S2-tabel in S1 File
De meest voorkomende bijwerkingen waren koorts, anorexia, opvliegers, koude rillingen, reactie op de injectieplaats en auto-immuunziekte. Zie Table 1
Of the 14 patients who received adoptive immune cell therapy, nine died during the study period. Five patients who had a durable response survived for at least 28 months and for a maximum of 76 months after tumor recurrence (Table 2 and S6 Fig in S1 File). There were no differences in terms of chemotherapy, re-irradiation, age-at-diagnosis of recurrent GBM, and sex between good and poor responders (Table 2). The median OS of adoptive-immune-cell-treated patients was 22.5 months (Fig 2A), and the median progression-free survival (PFS) was 10 months (Fig 2B). Five patients were alive for over 2 years and continued with activities of daily living. Four patients completed the adoptive immune-cell therapy (Fig 2C). One patient (A14) discontinued this therapy after the 11th expanded cell injection owing to our inability to obtain enough expanded immune cells over four attempts (S2 Table in S1 File). Adoptive immune-cell therapy was discontinued in nine patients because of tumor progression (S2 Table in S1 File).
Het volledige studierapport is gratis in te zien of te downloaden. Klik op de titel van het abstract.
Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial
Abstract
Glioblastoma multiforme (GBM) is an aggressive malignancy classified by the World Health Organization as a grade IV glioma. Despite the availability of aggressive standard therapies, most patients experience recurrence, for which there are currently no effective treatments. We aimed to conduct a phase I/IIa clinical trial to investigate the safety and efficacy of adoptive, ex-vivo-expanded, and activated natural killer cells and T lymphocytes from peripheral blood mononuclear cells of patients with recurrent GBM. This study was a single-arm, open-label, investigator-initiated trial on 14 patients recruited between 2013 and 2017. The immune cells were administered via intravenous injection 24 times at 2-week intervals after surgical resection or biopsy. The safety and clinical efficacy of this therapy was examined by assessing adverse events and comparing 2-year overall survival (OS). Transcriptomic analysis of tumor tissues was performed using NanoString to identify the mechanism of therapeutic efficacy. No grade 4 or 5 severe adverse events were observed. The most common treatment-related adverse events were grade 1 or 2 in severity. The most severe adverse event was grade 3 fever. Median OS was 22.5 months, and the median progression-free survival was 10 months. Five patients were alive for over 2 years and showed durable response with enhanced immune reaction transcriptomic signatures without clinical decline until the last follow-up after completion of the therapy. In conclusion, autologous adoptive immune-cell therapy was safe and showed durable response in patients with enhanced immune reaction signatures. This therapy may be effective for recurrent GBM patients with high immune response in their tumor microenvironments. Trial registration:The Korea Clinical Research Information Service database: KCT0003815, Registered 18 April 2019, retrospectively registered.
Discussion
This study reports a phase I/IIa clinical trial on autologous, adoptive, expanded, and activated immune-cell therapy with high proportions of NK cells or T lymphocytes from PBMCs for patients with recurrent GBM. It adopted a single arm and open-labeled design to evaluate safety, efficacy, and mechanism of action of the adoptive immune-cell therapy.
The most important consideration in immune-cell treatment is immunological reaction with severe adverse effects. In this study, most of the patients experienced adverse effects of grades 1 and 2 related to the adoptive immune-cell therapy without any severe immunological rejection (Table 2 and S5 Table in S1 File), which manifests as a cytokine storm [15,16]. The most frequent events were mild immune-related symptoms, such as fever, hot flushes, chills, injection-site reaction, and gastrointestinal symptoms, such as anorexia, nausea, and constipation (Table 2). The hematological symptoms related to the immune-cells therapy were mild and reversed with conventional treatment. The most severe adverse effect related to this adoptive immune-cell therapy was a grade 3 fever, which resolved without any complication (Table 2 and S5 Table in S1 File). During adoptive immune-cell therapy, severe adverse events of grades 4 and 5 occurred 6 times. Leukocytopenia occurred 3 times, and thrombocytopenia occurred once. These events were related to the salvage chemotherapy as they occurred after administration of the chemo-drug, ACNU or BCNU, they were treated with medication and transfusion. Other severe adverse events occurred in the poor response group and were related to tumor progression. Hydrocephalus and severe brain swelling occurred in one case. Taken together, these results suggest that this adoptive immune-cell therapy is safe.
An anticancer therapeutic agent must prolong the patient’s survival and slow the progression of tumor. In the case of GBM, standard treatment using temozolomide and radiation extends the mean OS by approximately 4 months [1,17]. However, this is much lower than the OS observed for other cancers, and extension of OS is extremely rare in recurrent GBM. Recurrent GBM is associated with an OS of 6–8 months despite the administration of adjuvant treatment [4,18,19]. The median OS of adoptive immune-cell-treated patients was 22.5 months, and the median PFS was 10 months. Five patients survived for more than 2 years after the recurrence of GBM. Although this trial was conducted in a small number of patients (14), prolonged OS and PFS are important indicators of efficacy. These results indicate that adoptive immune-cell therapy could be used to treat GBM; however, they will have to be validated in clinical trials on a large number of patients.
Recently, clinical trials have been conducted using several immune cells or neoadjuvant immune check point inhibitors and have shown durable responses with OS of over 2 years in some recurrent GBM patients [8–11,20]. In this study, 5 patients showed a good response with OS of more than 2 years (Fig 2C). Four patients presented a durable response to the adoptive immune-cell therapy, without progression, and with a fuzzy pattern of enhancement or a “soap bubble or Swiss cheese appearance” with cystic changes on MRI (S6-S8 Figs in S1 File and Fig 2D). The fuzzy, enhanced lesions increased gradually during therapy, followed by a time-dependent decrease after the therapy. A thickened pattern of enhancement was observed for up to 14 months after the first adoptive immune-cell therapy session, after which the degree of enhancement decreased. This response was considered to indicate pseudoprogression with high immune reaction. Patients who did not respond to the adoptive immune-cell therapy presented a thick pattern of gadolinium enhancement or progression of ventricle wall enhancement (S9 and S11 Figs in S1 File). It is not clear whether the thickened pattern of enhancement was pseudoprogression or radiation necrosis [21,22]. Except A13 patient, all of the participants received re-irradiation therapy as salvage treatment before the administration of the adoptive immune-cell therapy (S2 Table in S1 File). These MRI signatures, which may be pseudoprogression or radiation necrosis, were continuously observed in good responders for at least 1 year. Compared to other modes of immunotherapy, immune cells were transferred many times (maximum of 24) to recurrent GBM patients in this study. Long-term-immune boosting effects were observed in the MRI signatures, indicating a durable immune effect and longer survival.
We performed NanoString transcriptomic analysis to elucidate the mechanism of action of the adoptive immune-cell therapy used in this study. Our results demonstrated that immune-related genes were associated with a protective effect in terms of PFS or were up-regulated in good responders (Fig 3, S13 and S14 Figs, and S7 Table in S1 File). In addition, four annotated terms including “Immune Cell Localization to Tumors”, “Recognition of Cancer Cells by T-cells”, “Myeloid Cell Activity”, and “Common Signaling Pathways” were able to discriminate between good and poor responders (Fig 3). Hyper-immunoactivity was detected in good responders. Recently, analysis of omics data was able to establish a subtype of GBM with high resolution [23–26]. The subtypes, classified based on multi-omics, were proneural, neural, classical, and mesenchymal. Several previous studies have reported that the mesenchymal subtype GBM is characterized by a higher degree of immune cell infiltration than the other subtypes, and it is considered more suitable to immunotherapy [27–30]. Using public GBM transcriptomic data from TCGA, all genes that were significantly associated with a protective effect for PFS or those that were upregulated in good responders, were found to be overexpressed in the mesenchymal hyper-enriched cluster (S15 Fig in S1 File). This indicates that this immune cell therapy may be efficacious in patients with an immune-response tumor type, such as those with mesenchymal subtype GBM from the TCGA dataset. A vaccination clinical trial using dendritic cells has also reported that the mesenchymal type GBM showed a good prognosis [31].
In the present study, ex-vivo-expanded and activated immune cells were administered by intravenous injection. Therefore, trafficking and transport of the immune cells to the tumor microenvironment are very important. Several previous studies revealed that the BBB is destroyed to different levels in patients with GBM, allowing immune cell trafficking [32,33]. In this study, using transcriptomic analysis, we elucidated the mechanism of action of this immune cell therapy and found a component involving the movement of immune cells to the tumor in order to maximize their tumor-killing ability. Several chemokines, including CCL4, CCL3L1, and CCL20, were upregulated in good responders or were associated with a protective effect for PFS. Several studies have reported that the in vitro activation of NK cells with IL-2 leads to the production of CCR2, CCR4, CCR5, and CCR8 [34–36]. Notably, these NK cells demonstrate high chemo-attractive responses with various chemokines including CCL4 [34,37–40]. Tumor tissues with increased level of these chemokines may have an enhanced ability to attract immune cells, which would move towards such tumor cells after administration. In the poor responders, although many immune cells were administered, the immune cells could not move toward the tumor microenvironment as the chemotactic signal was weak. Radiologically, an encouraging aspect about our results is pseudoprogression. The iRANO criteria suggest that pseudoprogression, in the MR scan after immunotherapy, could be considered a therapeutic response with immune infiltration [13]. As a result, in the MRI, long-lasting pseudoprogression was detected in only four good responders (S6-S8 Figs in S1 File and Fig 2D) with no additional tumor progression, but not in poor responders (S9 Fig in S1 File). These results suggest that immune cells administered to good responders would reach the tumor site via chemotaxis as a result of the immune response in the cancer microenvironment.
Consequently, in good responders with mesenchymal subtype, immune cells might have reached the brain. Immunohistochemical stain demonstrated that the CD3, CD8 or CD16 positive cells were significantly more infiltrated in tissue during adoptive immune cell therapy compared with pre-Tx in A1 patient with a good response (S1-S16 Figs and supplemental data in S1 File). Furthermore, by presenting long-lasting pseudoprogression, which is considered a treatment response to immunotherapy, good responders could present a long survival benefit. However, we were not able to experimentally determine whether NK cells actually exert anticancer effects among the expanded immune cell populations from PBMCs. In addition, as this was a clinical phase I/IIa trial on the safety and minimal efficacy, sufficient statistical power was not obtained due to the small number of patients. Therefore, further evaluation is needed through phase II clinical trials in the future.
Conclusions
Autologous adoptive immune-cell therapy was safe and showed good clinical outcome. This therapy demonstrated durable responses in five patients without severe adverse effects, and transcriptomic analysis showed that the good responders had enhanced immune response signatures. Therefore, this adoptive immune-cell therapy may be effective in a group of recurrent GBM patients with enhanced immune signatures, such as those with mesenchymal subtype.
Gerelateerde artikelen
- Gepersonaliseerde vorm van immuuntherapie succesvol bij melanomen gegeven voor operatie doet hersentumor type Glioblastoma Multiforme van arts verdwijnen en er is nog geen teken van recidief na 1 jaar.
- mRNA vaccin doet hersentumoren type Glioblastoma razendsnel veranderen van koude tumoren in warme tumoren. Blijkt uit eerste klinische studie bij volwassen patienten en bevestigt resultaten uit dierstudies
- CAR-T celtherapie rechtstreeks toegediend in de hersenen doet tumorweefsel van Glioblastoma Multiforma snel slinken en soms zelfs verdwijnen.
- DCVax-L verbetert overall overleving en vermindert kans op recidief bij patiënten met nieuw gediagnosticeerd glioblastoom en recidiverend glioblastoom in vergelijking met beste standaardzorg
- Craniopharyngiomas, goedaardige inoperabele primaire hersentumoren van de hypofyse-hypothalamus-as met BRAF V600E mutaties reageren bijzonder goed op combinatiebehandeling van vemurafenib + cobimetinib
- Immuuntherapie met Natural Killer cellen en opgekweekte versterkte autologe T-cellen geeft verrassend goede resultaten bij patienten met een recidief van een hersentumor type glioblastoom multiforme
- Immuuntherapie met cocktail van 9 niet-toxische medicijnen - middelen bij hersentumoren van het type Glioblastoma Multiforme blijkt veilig en geeft veelbelovende resultaten bij eerste 9 patienten uit studie van prof. dr. Halatsch
- Lage tumor mutatie belasting geeft een langere overleving bij patienten met een recidief van een glioblastoom wanneer deze behandeld zijn met immuuntherapie met een gemoduleerd poliovirus of anti-PD medicijn
- Meisje van drie jaar komt en blijft in een complete remissie van een hersentumor glioblastoma met larotrectinib een zogeheten TRK medicijn op basis van haar ETV6–NTRK3 mutatie. copy 1
- Surviving terminal cancer: kunnen overlevenden van een hersentumor helpen kanker te overwinnen? Drie mannen overwonnen hun hersentumor - GBM - en 2 ervan zijn al 15 en 20 jaar vrij van kanker met eigen cocktail van bewezen niet-toxische middelen. copy 1 c
- Immuuntherapie met anti-PD medicijnen (pembrolizumab en / of nivolumab) geeft geen effect op overall overleving bij zwaar voorbehandelde patienten met glioblastoma multiforme
- Immuuntherapie met gemoduleerd poliovirus blijkt succesvol bij recidief van hersentumoren van het type glioblastoma multiforme graad IV
- Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
- immuuntherapie met rindopepimut een vaccin (gericht op EGFR mutatie) naast temozolomide geeft geen enkel verschil in overall overleving in vergelijking met alleen temozolomide bij hersentumoren Glioblastoma met weinig of geen restweefsel na operatie
- Immuuntherapie met dendritische celtherapie voor hersentumoren type glioblastoma multiforme geeft 20 en 14 procent overall overleving versus 4 en 0 procent op 3 en 5 jaar .
- Dendritische celtherapie bij glioblastoma multiforme graad IV direct na bestraling plus temodal geeft langere overall overleving. 46 procent leeft nog na 3 jaar
- Nivolumab faalt bij recidief van een hersentumor Glioblastoma multiforme. Fase III studie Checkmate 143 wordt stopgezet
- Immuuntherapie met specifiek geprepareerde dendritische cellen (APVACS) plus tetanus virus (CMV) geeft superieure duurzame resultaten op ziektevrije tijd en overall overleving
- Immuuntherapie met gemoduleerd herpesvirus - AdV-Tk therapy - na operatie zorgt voor hoog significant meer en langere overleving in vergelijking met standaardbehandeling bij hersentumoren Glioblastoma multiforme
- APVACS - actief gepersonaliseerde vaccins - ontwikkelen tegen kanker wordt doel van nieuw consortium van 14 organisaties - GAPVAC, waaronder LUMC Leiden
- Toca 511 & Toca FC, een vorm van immuuntherapie met een gemodificeerd virus in combinatie met 5-FU bij hersentumoren - glioblastoma multiforme, heeft de eerste patiënt in behandeling genomen
- Dendritische celtherapie gecombineerd met een vaccin gericht op CD-133 eiwitexpressie voor patiënten met een hersentumor glioblastoma multiforme wordt in fase I/II studie onderzocht
- Behandeling met een virus - Delta-24-RDG - voor hersentumoren - glioblastoma multiforme wordt onderzocht in een fase I /II studie in het VUmc - Amsterdam
- Dendritische celtherapie gecombineerd met zogeheten mRNA's - cellen uit tumoren - verdriedubbeld overlevingstijd van mensen met een hersentumor - glioblastoma multiforme. copy 1
- Vaccin gemaakt van eigen tumorweefsel (HSPPC-96) verlengt leven 2 tot 3 keer zo lang van mensen met een geheel of gedeeltelijke operabele hersentumor. Dit.blijkt uit tussenevaluatie van fase II studie gepresenteerd op ASCO 2011
- Dendritische celtherapie met autoloog vaccin gebaseerd op antigenen geeft significant langere ziektevrije tijd en overall overleving bij patiënten met een hersentumor - glioblastoom
- Dendritische celtherapie vooral ook succesvol toepasbaar bij hersentumoren
- Immuuntherapie bij hersentumoren: Dendritische cellen toegediend na operatie van hersentumoren zorgt voor opmerkelijk goede kansen op geen recidief aldus resultaten uit kleinschalige studie bij 23 patiënten.
- Immuuntherapie bij hersentumoren: Dendritische cellen toegediend na operatie van hersentumoren zorgt voor opmerkelijk goede kansen op geen recidief aldus resultaten uit kleinschalige studie bij 12 patiënten.
- Immuuntherapie met synthetisch vaccin brengt enkele kinderen met een hersentumor - glioblastoom in een totale remissie
- Vaccin dat hersentumoren (Glioblastoom multiforme) met EGFRvIII expressie bestrijdt geeft verdubbeling van overlevingstijd en progressievrije tijd bij nieuw gediagnosteerde patienten
- Neuroblastomen: Immuuntherapie met chimeric anti-GD2 antibody ch 14.18 verhoogt significant overall overleving na 2 jaar met 20% t.o.v. alleen chemotherapie plus stamceltherapie.
- Stamcellen uit eigen bloed naast zware chemokuren geeft kinderen met recidief van hersentumoren langere overlevingstijd en kans op totale genezing, maar ook overlijdt 1 op de 4 kinderen aan de gevolgen van de behandeling
- Virussen: Herpes virusachtig medicijn - G207 wordt in fase I trial onderzocht bij kwaadaardige Glioma tumoren waarvoor radiotherapie - bestraling of chemo niet meer werkt en dus uitbehandeld zijn.
- Immuuntherapie bij hersentumoren met vaccins en virussen waaronder Newcastle Disease Virus. Een overzicht van recente ontwikkelingen.
Plaats een reactie ...
Reageer op "Immuuntherapie met Natural Killer cellen en opgekweekte versterkte autologe T-cellen geeft verrassend goede resultaten bij patienten met een recidief van een hersentumor type glioblastoom multiforme"